Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies. There are no additional fees to attend once you have registered for CMHC Annual and meals or refreshments may be provided. Register for CMHC Annual today and attend these activities.
PME Lunch Symposium · Thursday, October 10, 2019 · 12:05pm – 1:05pm
Reviewing A1C and Cardiovascular Safety Data in T2D Therapies
Faculty: Joshua M. Stolker, MD
An endocrinologist/diabetologist or a cardiologist discuss a multidisciplinary approach to the management of adults living with type 2 diabetes (T2D). The presenter will review the clinical trial program for two GLP-1 RA agents, as well as present the CVOT data.
Visit the Novo Nordisk booth for more information.
PME Light Bites Symposium · Thursday, October 10, 2019 · 4:15pm – 5:15pm
Cardiovascular Patient Cases
Faculty: Eliot A. Brinton, MD
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
PME Light Bites Symposium · Thursday, October 10, 2019 · 5:20pm – 6:20pm
Expert Insights: Managing Cardiovascular Risk Based on a Landmark CV Outcomes Study
Faculty: George Grunberger, MD
Despite the benefits of LDL-C lowering, many patients on statin therapy with elevated triglycerides remain at risk for cardiovascular (CV) disease. In this presentation, Expert Insights: Managing Cardiovascular Risk Based on a Landmark CV Outcomes Study, the results from the CV outcomes trial, REDUCE-IT™, will be reviewed. REDUCE-IT compared the number of major adverse CV events in 8179 patients with statin-controlled LDL-C, elevated triglycerides, and other CV risk factors including established CVD and diabetes.
Visit the Amarin Pharma, Inc. booth for more information.
PME Dinner Symposium · Thursday, October 10, 2019 · 6:30pm – 7:30pm
Jardiance® (empagliflozin) tablets: Data from the comprehensive clinical development program
Faculty: James H. O’Keefe, MD
This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE. Attendees will also have the opportunity to ask the faculty questions about the data presented.
PME Dinner Symposium · Friday, October 11, 2019 · 6:30pm – 7:30pm
Understanding the Clinical Implications of Heart Failure and Renal Dysfunction in Your Patients With Type 2 Diabetes
Faculty: Peter A. McCullough, MD, MPH
The objectives of this presentation are to review the scope and impact of type 2 diabetes (T2D) by focusing on the risk and burden of heart failure (HF). An overview of HF and risk factors for HF in T2D will be discussed. Also discussed will be the assessment of risk and improving diagnosis of HF in patients with T2D in the primary care setting while recognizing that renal and cardiovascular disease are closely interconnected in patients with T2D. Please join us for this event.
PME Light Bites Symposium · Saturday, October 12, 2019 · 6:30pm – 7:15pm
Understanding CKD in T2D: The Risks, Recognition, and Clinical Management
Faculty: Peter A. McCullough, MD, MPH; Luiza Caramori, MD
Chronic kidney disease (CKD) develops in a substantial proportion of patients with diabetes and significantly increases risk for adverse cardiovascular and renal outcomes. Multiple factors can contribute to the development and progression of CKD, although the precise etiology continues to evolve. The deleterious impact of CKD progresses over time, but consequences emerge in early stage disease, raising the importance of adherence to guideline recommendations for diagnostic screening, continued monitoring, and coordination of care across specialties for patients with CKD.